TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 11, 2016, Pages 1930-1938

  Nygaard, U ^a,b   Hvid, M ^b   Johansen, C ^a   Buchner, M ^c   Folster Holst R ^c   Deleuran, M ^a   Vestergaard, C ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; INTERLEUKIN 31; INTERLEUKIN 33; SOMATOSTATIN RECEPTOR 2; THYMIC STROMAL LYMPHOPOIETIN; BIOLOGICAL MARKER; CYTOKINE; IL31 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN DERIVATIVE;

ADULT; ADULT DISEASE; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; ATOPIC DERMATITIS; CHILD; CHILDHOOD DISEASE; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ENDOPHENOTYPE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADULT; BIOMARKERS; CHILD; CHILD, PRESCHOOL; CYTOKINES; DERMATITIS, ATOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-33; INTERLEUKINS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; YOUNG ADULT;

EID: 84992392048     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13679     Document Type: Article

References (58)

1. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012; 67: 1475–1482.
2. Proudfoot LE, Powell AM, Ayis S et al. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol 2013; 169: 901–909.
3. Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045–1060.
4. Folster-Holst R. Management of atopic dermatitis: are there differences between children and adults? J Eur Acad Dermatol Venereol 2014; 28(Suppl 3): 5–8.
5. Schmitt J, Langan S, Deckert S et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013; 132: 1337–1347.
6. Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy 2012; 67: 969–975.
7. Ardern-Jones MR, Bieber T. Biomarkers in atopic dermatitis: it is time to stratify. Br J Dermatol 2014; 171: 207–208.
8. Jariwala SP, Abrams E, Benson A, Fodeman J, Zheng T. The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis. Clin Exp Allergy 2011; 41: 1515–1520.
9. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006; 203: 269–273.
10. Salimi M, Barlow JL, Saunders SP et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 2013; 210: 2939–2950.
11. Tamagawa-Mineoka R, Okuzawa Y, Masuda K, Katoh N. Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol. 2014; 70: 882–888.
12. Savinko T, Matikainen S, Saarialho-Kere U et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 2012; 132: 1392–1400.
13. Cevikbas F, Steinhoff M. IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol 2012; 132: 1326–1329.
14. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 2015; 115: 3B–7B.
15. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: Getting the itch out? Clin. Rev. Allergy Immunol. 2015; 1: 1–30.
16. Castellani ML, Salini V, Frydas S et al. Interleukin-31: a new cytokine involved in inflammation of the skin. Int J Immunopathol Pharmacol 2006; 19: 1–4.
17. Grimstad O, Sawanobori Y, Vestergaard C et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009; 18: 35–43.
18. Cevikbas F, Wang X, Akiyama T et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 2014; 133: 448–460.
19. Hawro T, Saluja R, Weller K, Altrichter S, Metz M, Maurer M. Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy 2014; 69: 113–117.
20. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980; 92: 44–47.
21. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23–31.
22. Kragstrup TW, Vorup-Jensen T, Deleuran B, Hvid M. A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-animal IgG antibodies in plasma from arthritis patients. Springerplus 2013; 2: 263.
23. Nygaard U, Vestergaard C, Johansen C, Deleuran M, Hvid M. Measuring serum concentrations of interleukin-33 in atopic dermatitis is associated with potential false positive results. SpringerPlus 2016; 5: 1–4.
24. Thijs JL, Nierkens S, Herath A et al. A panel of biomarkers for disease severity in atopic dermatitis. Clin Exp Allergy 2015; 45: 698–701.
25. Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015; 15: 453–460.
26. Takai T. TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergology International 2012; 61: 3–17.
27. Sonkoly E, Muller A, Lauerma AI et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411–417.
28. Lee EB, Kim KW, Hong JY, Jee HM, Sohn MH, Kim KE. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. Pediatr Allergy Immunol 2010; 21: e457–e460.
29. Nakamura K, Tsuchida T, Tsunemi Y, Saeki H, Tamaki K. Serum thymic stromal lymphopoietin levels are not elevated in patients with atopic dermatitis. J Dermatol 2008; 35: 546–547.
30. Chauhan A, Singh M, Agarwal A, Paul N. Correlation of TSLP, IL-33, and CD4 + CD25 + FOXP3 + T regulatory (Treg) in pediatric asthma. J Asthma 2015; 52: 868–872.
31. Hamzaoui A, Berraies A, Kaabachi W, Haifa M, Ammar J, Kamel H. Induced sputum levels of IL-33 and soluble ST2 in young asthmatic children. J Asthma 2013; 50: 803–809.
32. Vocca L, Di Sano C, Uasuf CG et al. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology 2015; 220: 954–963.
33. Raap U, Weissmantel S, Gehring M, Eisenberg AM, Kapp A, Folster-Holst R. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr Allergy Immunol 2012; 23: 285–288.
34. Baumann R, Rabaszowski M, Stenin I et al. The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms. Clin Transl Allergy 2012; 2: 13–13.
35. Lei Z, Liu G, Huang Q et al. Original article: SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy 2008; 63: 327–332.
36. Raap U, Wichmann K, Bruder M et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 2008; 122: 421–423.
37. Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 2011; 25: 334–339.
38. Cheon BR, Shin JE, Kim YJ et al. Relationship between serum 25-hydroxyvitamin D and interleukin-31 levels, and the severity of atopic dermatitis in children. Korean J Pediatr 2015; 58: 96–101.
39. Kim S, Kim HJ, Yang HS, Kim E, Huh IS, Yang JM. IL-31 serum protein and tissue mRNA levels in patients with atopic dermatitis. Ann Dermatol 2011; 23: 468–473.
40. Ott H, Wilke J, Baron JM, Hoger PH, Folster-Holst R. Soluble immune receptor serum levels are associated with age, but not with clinical phenotype or disease severity in childhood atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 395–402.
41. Piancatelli D, Bellotta L, Del Beato T, Duse M, Della Penna MR. Total IL-12 levels are increased in paediatric atopic dermatitis: correlations with age and disease severity. Int J Immunopathol Pharmacol 2008; 21: 359–365.
42. Chen JY, Fu LS, Chu JJ, Chen HC, Chi CS. Plasma soluble CD30 level correlates negatively with age in children. J Microbiol Immunol Infect 2007; 40: 168–172.
43. Krampera M, Vinante F, Tavecchia L et al. Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol 1999; 117: 291–297.
44. Cornelissen C, Marquardt Y, Czaja K et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 2012; 129: 426–433, 433 e421-428.
45. Seltmann J, Roesner LM, von Hesler FW, Wittmann M, Werfel T. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 2015; 135(): e1654.
46. Kim JH, Bae HC, Ko NY et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J Allergy Clin Immunol 2015; 136(): e209.
47. Kim BS, Siracusa MC, Saenz SA et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 2013; 5: 170ra116.
48. Kitajima M, Lee HC, Nakayama T, Ziegler SF. TSLP enhances the function of helper type 2 cells. Eur J Immunol 2011; 41: 1862–1871.
49. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008; 126: 332–337.
50. Howell MD, Kim BE, Gao P et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120: 150–155.
51. van den Bogaard EH, Bergboer JG, Vonk-Bergers M et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 2013; 123: 917–927.
52. Hvid M, Johansen C, Deleuran B, Kemp K, Deleuran M, Vestergaard C. Regulation of caspase 14 expression in keratinocytes by inflammatory cytokines–a possible link between reduced skin barrier function and inflammation? Exp Dermatol 2011; 20: 633–636.
53. Ryu WI, Lee H, Kim JH, Bae HC, Ryu HJ, Son SW. IL-33 induces Egr-1-dependent TSLP expression via the MAPK pathways in human keratinocytes. Exp Dermatol. 2015; 24: 857–683.
54. Wilson SR, The L, Batia LM et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013; 155: 285–295.
55. Neis MM, Peters B, Dreuw A et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006; 118: 930–937.
56. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103–110.
57. Miller AM, Xu D, Asquith DL et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339–346.
58. Hjuler KF, Bottcher M, Vestergaard C, Deleuran M, Raaby L, Botker HE et al. Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. Am J Med. 2015; 128: 1325–1334.e2.